
25
6 SUMMARY OF CLINICAL STUDIES
6.1 Objectives
The primary objective of the clinical study was to evaluate the safety and
effectiveness of a previous version of the device (Zenith AAA Endovascular
Graft) as an alternative to open surgical repair in the primary treatment
of infrarenal abdominal aortic aneurysms. Study hypotheses examined
whether standard risk patients experienced less 30-day morbidity, non-
inferior 30-day survival rates, non-inferior 12-month survival rates,
non-inferior 12-month treatment success and improved clinical utility
measures compared to surgical control patients. Safety was determined by
evaluating whether the Zenith AAA Endovascular Graft subjects would have
reduced 30-day morbidity, non-inferior 30-day and 12-month survival and
non-inferior 12-month treatment success compared to the subjects treated
with open surgical treatment. Effectiveness was based on exclusion of the
aneurysm including the absence of any endoleak, the absence of aneurysm
enlargement (≥5 mm) and the absence of major device adverse events
evaluated through one year follow-up. Secondary objectives included an
assessment of clinical benefit and quality-of-life measures.
6.2 Study Design
The U.S. clinical study was a multicenter, non-randomized study comparing
standard medical risk patients who received an endovascular graft to an
open surgical control. There were two additional study arms for high medical
risk and roll-in treatment groups. Fifteen centers enrolled 200 standard risk,
80 surgical control, 100 high risk and 52 roll-in patients. The control group
included patients whose vascular anatomy may not have been suitable for
endovascular AAA repair. Follow-up evaluations were scheduled for pre-
discharge, 1 month, 6 months, 12 months and 24 months. Patient follow-up
and accountability at 1 month, 12 months and 24 months are presented in
Table 6.2.1, as these were the primary data analysis time points. Imaging
data provided in this summary are based on findings from an independent
centralized image analysis laboratory (Core Lab), which reviewed CT scans
and abdominal X-rays to assess aneurysm diameter changes, device and
relative component migration, device integrity (wire and graft) and the
presence and type of endoleaks. Clinical events were adjudicated by an
independent clinical events committee, and safety was monitored by a data
safety monitoring committee.
Surgical and Zenith standard risk patients met identical pathophysiologic
risk criteria. The endovascular groups excluded circumferential thrombus
in the proximal neck, proximal neck less than 15 mm in length, outer wall
to outer wall proximal neck diameter less than 18 mm or greater than 28
mm, severe proximal neck angulation, outer wall to outer wall iliac artery
diameter less than 7.5 mm or greater than 20 mm at distal fixation site or
iliac artery distal fixation site less than 10 mm in length.
Patients were considered at higher risk for surgical repair if they had age
greater than 80, baseline creatinine >2.0 mg/dl, home oxygen therapy,
FEV
1
<1 liter, ejection fraction <25%, disabling COPD, New York Heart
Classification 3 or 4, hostile abdomen, dialysis, MI within last 6 months,
medically intractable hypertension, previous stroke with residual deficit,
cultural objection to receipt of blood or blood products, previous renal
bypass surgery or inflammatory aneurysm.
Before enrolling patients into the pivotal trial, centers without Zenith AAA
Endovascular Graft experience were required to treat initial patients under
the supervision of a proctor. These roll-in patients were a combination of
standard and high risk patients and were followed according to the same
schedule as the patients in the pivotal trial.
Table 6.3.1 Comparison of Subject Characteristics
Item
Zenith Standard Risk
Surgical Standard Risk
P
value
Zenith High Risk
Zenith Roll-in
Age (years)
71 ± 7
69 ± 7
.03
77 ± 7
74 ± 8
Gender male
94%
(187/200)
89%
(71/80)
.22
92%
(92/100)
90%
(47/52)
Current medical conditions
16%
(31/195)
25%
(19/76)
.12
24%
(23/96)
9.6%
(5/52)
Peripheral vascular disease
Hypertension
64%
(127/200)
83%
(65/78)
.001
68%
(67/99)
67%
(35/52)
Renal failure
0.0%
(0/197)
0.0%
(0/79)
>.99
5.2%
(5/97)
1.9%
(1/52)
COPD
20%
(39/199)
18%
(14/78)
.87
34%
(33/98)
22%
(11/51)
Thromboembolic event
4.5%
(9/199)
7.7%
(6/78)
.38
7.1%
(7/99)
1.9%
(1/52)
Liver disease
2.1%
(4/192)
5.1%
(4/79)
.24
1.0%
(1/99)
1.9%
(1/52)
Diabetes mellitus
12%
(24/199)
15%
(12/79)
.55
17%
(17/99)
14%
(7/51)
Insulin-dependent
17%
(4/24)
8.3%
(1/12)
.65
24%
(4/17)
43%
(3/7)
Previous medical conditions
39%
(74/192)
29%
(23/80)
.13
35%
(34/98)
35%
(18/52)
MI
Congestive heart failure
5.0%
(10/199)
12%
(9/78)
.07
16%
(16/100)
10%
(5/50)
Angina
49%
(98/198)
39%
(31/79)
.14
45%
(44/98)
44%
(23/52)
Arrhythmia
20%
(40/197)
22%
(17/78)
.87
28%
(27/98)
24%
(12/51)
Cerebrovascular disease
9.5%
(19/199)
16%
(13/79)
.14
20%
(20/99)
9.8%
(5/51)
Systemic infection
1.0%
(2/196)
0.0%
(0/78)
>.99
3.1%
(3/97)
0.0%
(0/49)
Cancer
22%
(43/200)
19%
(15/80)
.74
31%
(31/99)
29%
(15/51)
Family history of aneurysmal disease
16%
(24/150)
27%
(17/63)
.09
14%
(11/77)
26%
(10/38)
Previous surgery at site
10%
(20/200)
15%
(12/79)
.22
10%
(10/99)
14%
(7/51)
Previous radiation at site
0.5%
(1/197)
0.0%
(0/79)
>.99
2.0%
(2/100)
2.0%
(1/51)
Excessive alcohol use
3.6%
(7/193)
10%
(8/77)
.04
3.1%
(3/96)
4.0%
(2/50)
Tobacco use
10%
(20/193)
5.0%
(4/80)
14%
(13/96)
24%
(12/49)
Never smoked
Past smoker
69%
(133/193)
60%
(48/80)
.03
69%
(66/96)
57%
(28/49)
Still smokes
21%
(40/193)
35%
(28/80)
18%
(17/96)
18%
(9/49)
Due to inclusion criteria, high risk patients were older (
P
<.001), had more renal failure (
P
=.004), COPD (
P
=.01), congestive heart failure (
P
=.004) and
cerebrovascular disease (
P
=.02) than standard risk patients.
Table 6.2.1 Patient Follow-Up and Accountability
1
Treatment
Zenith Standard Risk
Surgical Standard Risk
Interval
1 mo.
12 mo.
24 mo.
1 mo.
12 mo.
24 mo.
No device
1
1
2
1
2
0
0
n/a
Conversion to open repair
0
2
2
2
2
n/a
n/a
n/a
Expired
1
7
17
2
3
n/a
Withdrawn/lost to follow-up
0
0
2
0
4
n/a
Available
198
190
178
78
73
n/a
Site CT imaging
191
168
110
69
58
n/a
Core lab CT imaging
190
165
99
69
59
n/a
Site KUB imaging
179
153
108
n/a
n/a
n/a
Core lab KUB imaging
178
149
93
n/a
n/a
n/a
Site evaluated for endoleak
187
163
107
n/a
n/a
n/a
Core lab evaluated for endoleak
161
148
92
n/a
n/a
n/a
Site evaluated for aneurysm enlargement
n/a
149
104
n/a
n/a
n/a
Core lab evaluated for aneurysm enlargement
n/a
151
94
n/a
n/a
n/a
1
Data analysis sample size varies for each of the time points above and in the following tables. This variability is due to patient availability for follow-up,
as well as quantity and quality of images available from specific time points for evaluation. For example, the number and quality of images available for
evaluation of endoleak at 12 months is different than the number and quality of images available at 24 months due to variation in the number of image
exams performed, the number of images provided from the clinical site to the Core Lab and/or the number of images with acceptable evaluation quality.
Totals at time points are not cumulative, unless otherwise noted.
2
Totals at time points are cumulative.
6.3 Patient Demographics
Tables 6.3.1 and 6.3.2 compare the subject characteristics and initial aneurysm diameter of the Zenith AAA Endovascular Graft and open surgical population,
respectively.
Содержание Zenith Flex
Страница 9: ......
Страница 92: ...92 42 8 Captor Flexor 9 10 14 2 4 1 2 3 43 Spiral Z 30 mm 4 1 5 5 18 44 6 7 45 8 9...
Страница 219: ......